BioMotiv: An Rx For Asset Financing Without The Venture Headache
This article was originally published in Start Up
Backed by a Cleveland family foundation and powerful hospital group, the for-profit BioMotiv wants to do biopharma asset financing on its own terms.
You may also be interested in...
Flexion Therapeutics had the pedigree, determination, and corporate connections to source and speed to clinical proof-of-concept its in-licensed pharma assets, and it planned to build a business around getting paid to do so. But a funny thing happened on the way to the bank.
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.